Literature DB >> 19336747

Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.

A John Barrett1, Elaine Sloand.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19336747      PMCID： PMC2663605          DOI： 10.3324/haematol.2009.006080

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Authors:  Elaine M Sloand; Lori Mainwaring; Monika Fuhrer; Shakti Ramkissoon; Antonio M Risitano; Keyvan Keyvanafar; Jun Lu; Atanu Basu; A John Barrett; Neal S Young
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

2.  Function and X chromosome inactivation analysis of B lymphocytes in myelodysplastic syndromes with immunological abnormalities.

Authors:  M Okada; T Okamoto; Y Takemoto; A Kanamaru; E Kakishita
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

3.  CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins.

Authors:  Elaine M Sloand; Loretta Pfannes; Gubin Chen; Simant Shah; Elena E Solomou; John Barrett; Neal S Young
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

4.  Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation.

Authors:  Lei Ying; Jillian Marino; S Perwez Hussain; Mohammed A Khan; Shaojin You; Anne B Hofseth; Glennwood E Trivers; Dan A Dixon; Curtis C Harris; Lorne J Hofseth
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

5.  Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.

Authors:  Guibin Chen; Weihua Zeng; Akira Miyazato; Eric Billings; Jaroslaw P Maciejewski; Sachiko Kajigaya; Elaine M Sloand; Neal S Young
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

6.  Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

Authors:  Elaine M Sloand; Colin O Wu; Peter Greenberg; Neal Young; John Barrett
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

7.  Chromosomal instability in ulcerative colitis is related to telomere shortening.

Authors:  Jacintha N O'Sullivan; Mary P Bronner; Teresa A Brentnall; Jennifer C Finley; Wen-Tang Shen; Scott Emerson; Mary J Emond; Katherine A Gollahon; Alexander H Moskovitz; David A Crispin; John D Potter; Peter S Rabinovitch
Journal:  Nat Genet       Date:  2002-09-23       Impact factor: 38.330

8.  Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression.

Authors:  James N Kochenderfer; Sumiko Kobayashi; Eric D Wieder; Chunliu Su; Jeffrey J Molldrem
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

9.  Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles.

Authors:  J J Molldrem; Y Z Jiang; M Stetler-Stevenson; D Mavroudis; N Hensel; A J Barrett
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

10.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).

Authors:  Shahram Y Kordasti; Wendy Ingram; Janet Hayden; David Darling; Linda Barber; Behdad Afzali; Giovanna Lombardi; Marcin W Wlodarski; Jaroslaw P Maciejewski; Farzin Farzaneh; Ghulam J Mufti
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113
View more
  16 in total

1.  Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.

Authors:  Maryam Hejazi; Angela R Manser; Julia Fröbel; Andrea Kündgen; Xiaoyi Zhao; Kathrin Schönberg; Ulrich Germing; Rainer Haas; Norbert Gattermann; Markus Uhrberg
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 2.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

3.  MDS and GCA: a prognostic dilemma.

Authors:  Neha G Narula; Andy Abril
Journal:  Clin Rheumatol       Date:  2015-06-18       Impact factor: 2.980

4.  Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.

Authors:  Angel F Remacha; Beatriz Arrizabalaga; Javier Bueno; Juan Muñoz; Joan Bargay; Carme Pedro
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

5.  Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome.

Authors:  Gláucia A S Guelsin; Camila Rodrigues; Jeane E L Visentainer; Paula De Melo Campos; Fabíola Traina; Simone C O Gilli; Sara T O Saad; Lilian Castilho
Journal:  Blood Transfus       Date:  2014-06-12       Impact factor: 3.443

Review 6.  The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.

Authors:  Amy E DeZern; Mikkael A Sekeres
Journal:  Oncologist       Date:  2014-06-04

Review 7.  The genetic basis of myelodysplasia and its clinical relevance.

Authors:  Mario Cazzola; Matteo G Della Porta; Luca Malcovati
Journal:  Blood       Date:  2013-10-17       Impact factor: 22.113

8.  Modeling regulatory network topology improves genome-wide analyses of complex human traits.

Authors:  Xiang Zhu; Zhana Duren; Wing Hung Wong
Journal:  Nat Commun       Date:  2021-05-14       Impact factor: 14.919

9.  Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.

Authors:  Panagiotis T Diamantopoulos; Maria Michael; Olga Benopoulou; Efthymia Bazanis; George Tzeletas; John Meletis; George Vayopoulos; Nora-Athina Viniou
Journal:  Virol J       Date:  2012-01-03       Impact factor: 4.099

10.  Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes.

Authors:  Miyoung Kim; Seungwoo Hwang; Kiejung Park; Seon Young Kim; Young Kyung Lee; Dong Soon Lee
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.